We utilized a genomic analysis of the response of neuronal GT1-7 cells to enterostatin to identify pathways responsive to this peptide. This information, together with reported properties of the enterostatin receptor, suggested that enterostatin may have an effect on angiogenesis. Method: To investigate this hypothesis, we studied the effect of enterostatin as an antiangiogenic agent in two angiogenic tissue culture model systems.
Introduction
Enterostatin is recognized as a satiety peptide that selectively inhibits fat intake in rodents when it is administered either centrally or peripherally. [1] [2] [3] Enterostatin, a pentapeptide, is released from its parent procolipase molecule by proteolysis. It is produced in the exocrine pancreas, gastrointestinal tract and in specific regions of the brain. 1, 4, 5 In addition to its effects on feeding behavior, enterostatin also has metabolic effects, directly promoting fatty acid oxidation in muscle 6 and inhibiting insulin secretion. 7 The enterostatin receptor has been identified as the b-subunit protein of the F1-ATPase complex. [8] [9] [10] While this is normally regarded as a mitochondrial protein, a number of studies have shown that both the b-and a-subunits of this F1-ATPase complex are also localized in the plasma membrane of a number of different tissues and cell types. 8, [11] [12] [13] [14] [15] Indeed, one mechanism through which angiostatin inhibits angiogenesis is through binding to the a-subunit protein within the plasma membrane. 12, 13 The possibility that a-and b-subunits of F1-ATPase are bound together as heterodimers within the plasma membrane suggested the possibility that enterostatin might also affect the angiogenic pathway. Analysis of the data from a genomic study on a GT1-7 neuronal cell line aimed at understanding the mechanism of enterostatin effects in the brain identified the possibility that enterostatin affected the pathway of angiogenesis. The intracellular signaling pathways through which enterostatin initiates its biological response have been unclear until recently. We have shown that the enterostatin stimulation of fatty acid oxidation in human myocytes is associated with an activation of phosphorylated AMP kinase (pAMPK), 6 the inhibitory response on insulin secretion is associated with changes in cyclic AMP signaling 7 and the enterostatin regulation of AgRP gene expression in neuronal GT1-7 cells is associated with changes in both the cAMP and MAP kinase ERK pathways (M Park and DA York, unpublished observations). pAMPK is an early signal that initiates the angiogenic response in a number of tumor cell lines and may regulate the expression of vascular endothelial growth factor A (VEGF-A), a recognized marker gene for angiogenesis. 16, 17 These data, together with the genomics effects which we report in this study, suggested that a study of the potential effects of enterostatin on angiogenesis was warranted.
Methods
Peptides Enterostatin (APGPR) was synthesized by solid-phase chemistry and purified by high-performance liquid chromatography to be greater than 90% purity by Harkness Pharmaceutical Company (San Diego, CA, USA). Peptides for cell cultures were dissolved in Hank's balanced salt solution (Invitrogen, Carlsbad, CA, USA) and stored in aliquots at À20 1C until used.
Cell culture GT1-7 neuronal cells were a kind gift from Dr P Mellon (University of California, San Diego, CA, USA). Cells were cultured and maintained in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum (Invitrogen), 100 U ml À1 of penicillin (Invitrogen) and 100 mg ml À1 of streptomycin (Invitrogen) at 37 1C in 5% CO 2 atmosphere. Cells below passage 20 were used. Cells were incubated in the absence or presence of enterostatin (10, 100 or 1000 nM) for 1 h before harvesting for RNA extraction. HepG2 human hepatoma cells were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were cultured and maintained in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum (Invitrogen), 100 U ml À1 of penicillin (Invitrogen) and 100 mg ml À1 of streptomycin (Invitrogen) at 37 1C in 5% CO 2
atmosphere. Cells below passage 20 were used. To promote an angiogenic response, HepG2 cells were incubated in the absence of glucose for 4 h. The AMPK activator 5-aminoimidazole-4-carboximide ribonucleoside (AICAR) was added at the beginning of this 4-h incubation period in some experiments. Enterostatin was added 1 h before harvesting the cells for mRNA analyses (after 3 h incubation in glucosefree media) or 15 min prior to the end of the 4-h incubation period when cells were harvested for AMPK assays.
Human adipose tissue angiogenesis assay This method has been described in detail previously. 18 Subcutaneous adipose tissue was removed from the anterior abdominal area of morbidly obese subjects undergoing gastric bypass surgery through the incisions placed to insert the laparoscopic instruments. The fat was placed directly into sterile assay media (see below), transported directly to the laboratory from the surgery in the sterile container and processed under a laminar flow hood. The tissue was cut into fragments approximately 1 mm thick and 2 mm in diameter. These fragments were placed in 96-well plates containing 4 ml human thrombin solution (0.05 IU in 4 mcl per well) and covered with 100 ml clotting media (3 mg ml À1 fibrinogen;
Sigma Chemical Co., St Louis, MO, USA), 0.5% e-amino caproic acid (Sigma Chemical Co.) in angiogenesis media containing 100 U ml À1 penicillin, 100 U ml À1 streptomycin sulfate and 2.5 mg ml À1 amphotericin b in Medium 199
(GibcoBRL, Gaithersburg, MD, USA). The mixture was allowed to clot by incubation in 6% CO 2 , 94% air at 37 1C in a humidified incubator. After the media had gelled overnight, the fat-containing clot was supplemented with 100 ml angiogenesis media containing 20% fetal bovine serum (GibcoBRL). The total volume of each well was 200 ml. There were nine replicates for each dose of enterostatin (0, 1, 10, 100 and 1000 nM). The angiogenesis media were replaced every 48 h and appropriate concentrations of fresh enterostatin were added. Wells were evaluated for the angiogenic response as described by Greenway et al. 18 An observer unbiased to the treatment protocols evaluated the angiogenic response using a semi-quantitative visual rating scale. 19 Essentially, the tissue was viewed under an inverted microscope, visually divided into four quadrants and each quadrant was given a numeric score from 0 to 4 based on the neovessel's length, density and percentage of the quadrants' circumference involved with the angiogenic response. Numeric results from the four quadrants were summed and expressed as an angiogenic index ranging from 0 (no neovessels apparent in any quadrant) to 16 (highly vascularized in all four quadrants). This rating scale has been validated by Hornick et al. 20 using multiple independent observers. Images of the clot were taken through a dissecting scope with a Leica MZ7 and a SPOT Insight digital camera.
Human umbilical vein angiogenesis assay
This was performed essentially as first described by Brown et al. 21 A fragment of human placental blood vessel was embedded in a fibrin gel in 96-well plates and cultured for 7-21 days essentially as described above for the adipose tissue assay. There were five replicates for each dose of enterostatin used.
RNA isolation and semi-quantitative PCR RNA was extracted from tissue or cells using TriReagent (Molecular Research, Cincinnati, OH, USA). RNA was treated Microarray gene analysis GT1-7 cells were incubated in the presence of enterostatin at one of four concentrations (0, 10, 100 and 1000 nM) for 1 h before harvesting and isolation of RNA as described above. RNA quality was visually assessed using agarose gel electrophoresis and quantified by UV spectrophotometric analysis (A 260 nm and A 280 nm ). All RNA had A 260 /A 280 ratios greater than 1.75 and less than 2.10. RNA integrity was checked using an RNA 6000 nano lab chip kit (Agilent Technologies, Foster City, CA, USA). The high-density microarrays used in this study were generated by the Genomics Core Microarray Facility at the Pennington Biomedical Research Center using a Gene Machines OmniGrid Microarrayer (San Carlos, CA, USA) to spot 70-mer oligonucleotides (mouse library versions 1.0 and 2.0; Operon Biotechnologies Inc., Huntsville, AL, USA) onto poly-lysine-coated glass microscope slides. The mouse libraries used for printing slides represent over 19 000 well-characterized genes; information concerning gene specifics can be located on the Operon website (http://omad.operon.com/mouse/index.php and http://omad. operon.com/mouse2/index.php). Equal amounts (6 mg) of total RNA from each of the enterostatin doses and the control untreated cells were subjected to reverse transcription with oligo(dT), labeled with Cy3 and Cy5 dyes using the Micromax TSA labeling and detection kit protocol (Perkin Elmer Life Sciences, Inc., Boston, MA, USA) and hybridized to in-house spotted slides. The TSA labeling method uses a tyramide signal amplification process, and is highly sensitive, allowing for the use of very small amounts (as little as 2 mg) of total RNA with consistent and reproducible signal amplification across arrays. cDNA from enterostatin-treated groups (10, 100 and 1000 nM enterostatin) was labeled with Cy5 and hybridized against control cDNA labeled with Cy3. Control Cy5-labeled cDNA was also compared to control Cy3 cDNA. Slides were scanned using a GSI Lumonics ScanArray 5000 laser scanner (Perkin Elmer Life Sciences Inc.) at a relatively low and a relatively high laser intensity and expression data were analyzed using the QuantArray V3.0 software package (Perkin Elmer Life Sciences Inc.). The data were then normalized using a subarray-by-subarray LOWESS (locally weighted regression and scatterplot smoothing) statistical algorithm developed in-house at the Pennington Biomedical Research Center. Using this system, we identified genes that were upregulated by at least 1.7 Â or downregulated to at least 0.7-fold at the lowest dose of enterostatin and showed a dose-response relationship with enterostatin. The data were then subjected to pathway analysis using the Panther software (www.appliedbiosystems/panther) and this identified genes associated with angiogenesis that were regulated in response to enterostatin.
Western blots
To extract total protein, cells were washed twice with cold Dulbecco's phosphate-buffered saline (Invitrogen) after incubation with enterostatin. Ice-cold whole cell lysis buffer (200 ml) (50 mM KCl, 1% NP-40, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.8, 10 mg ml À1 leupeptin, 20 mg ml À1 aprotonin, 125 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 1 mM orthovanadate) was added to cells and recovered by spatula. Cells were sonicated and centrifuged at 4 1C, 14 000 r.p.m. for 15 min. 50 mg of total protein from each samples was separated on 8 or 10% SDSpolyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (Pierce, Rockford, IL, USA) membrane for 3 h at 80 V using transfer buffer (24 mM Tris, 194 mM glycine and 20% methanol). Membrane was blocked for 2 h at room temperature with 5% milk buffer (5% non-fat milk buffer; Tris-buffered saline with Tween-20) and incubated overnight at 4 1C with phospho-specific primary antibody in 1% milk buffer (1% non-fat milk in Tris-buffered saline) After washing four times with Tris-buffered saline, the membrane was incubated with appropriate secondary antibody for 1 h at room temperature and it was incubated with ECL detection kit (Pierce) and exposed to X-ray film (Phoenix, Hayward, CA, USA) and developed using X-Omat (Kodak, Rochester, NY, USA). Antibodies to pAMPK (2531) was obtained from Cell Signaling (Danvers, MA, USA) and b-actin antibody (ab6276) used as a control was purchased from Abcam (Cambridge, UK) and used at concentrations of 1:1000 and 1:4000, respectively.
Data analysis
The angiogenesis index data are expressed as means ± s.e.m. Statistical analysis was performed by one-way analysis of variance with repeat measures (time) when appropriate. Post hoc analysis for individual groups was performed with the Neumann-Keuls test. Po0.05 was taken as statistically significant.
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Results
Gene expression in GT1-7 cells in response to enterostatin As part of the study to understand the effects of enterostatin on neurons, we undertook a gene array experiment using the GT1-7 neuronal cell line. Genes that were increased in expression by more than 1.7-fold in response to enterostatin or inhibited by 0.7-fold were subject to pathway analysis using the Panther Analysis vehicle (www.panther.appliedbiosystems.com). This indicated that a number of pathways were influenced, including a total of 22 genes related to angiogenesis that were regulated by enterostatin. Table 1 shows the fold changes of specific genes related to angiogenesis in response to the 10 nM enterostatin dose, the lowest dose used in the microarray studies. The responsive genes included VEGF-A, and a number of frizzled homologs (homologs 2 and 5 (Fzd2 and Fzd5) and secreted frizzledrelated sequence protein 4 (Sfrp4)). Subsequent semi-quantitative PCR of several of these genes (Fzd2, Dvl1 and Raf1, data not shown) confirmed the enterostatin-induced changes in expression that were identified by the microarray analysis.
Enterostatin inhibits angiogenesis
To obtain proof-of-function data that enterostatin affected angiogensis, we chose to utilize two well-characterized in vitro assay systems, the human adipose tissue angiogenesis assay and the human umbilical vein angiogenesis assay. Figure 1A illustrates the effect of enterostatin (1 nM) for 15 days on the development of new blood vessels in human adipose tissue incubated in cell culture. A time course of the response ( Figure 1B ) identified a lag period of 3 days before the initial appearance of new blood vessels after which there was a rapid development that began to plateau by 13 days. Enterostatin had a U-shaped dose-response effect to inhibit this angiogenesis with the optimal inhibition at 1 nM ( Figure 1B) . The effect of enterostatin on angiogenesis in the human placental vein model is shown in Figure 2 . Because there was significant variation in both the level of angiogenesis and the response to enterostatin across individual experiments, three representative replicate experiments are illustrated. Again enterostatin inhibited angiogenesis with a U-shaped dose-response curve with maximal inhibition at 10-100 nM.
Enterostatin inhibits pAMPK and VEGF-A gene expression in HepG2 cells incubated in the absence of glucose
To study the signaling pathways that might underlie the enterostatin inhibition of angiogenesis, we used a model developed by Yun et al. 22 who reported that a prostate tumor cell line DU 145 responds to glucose deprivation, an angiogenic stimulus, and survives by activating pAMPK and increasing the expression of Glut1 and VEGF-A. Likewise HepG2 cells, a liver cell tumor line, incubated in the absence of glucose for 4 h showed a big increase in pAMPK and a smaller increase in VEGF-A mRNA levels ( Figure 3a ) Enterostatin reduced the level of pAMPK in HepG2 cells incubated in the absence of glucose within 15 min at all doses tested (Figure 4a ). Likewise VEGF-A mRNA levels were decreased by incubation with enterostatin for 1 h at concentrations of 10 nM and greater, although no effect was seen at the lowest (1 nM) dose (Figure 4b ).
The AMPK activator AICAR increases VEGF-A expression
HepG2 cells were incubated in the absence or presence of 5 mM glucose for 4 h and the effect of AICAR (1 mM) on AMPK activity and VEGF-A gene expression was investigated. The presence of low concentrations of glucose attenuated the level of pAMPK (Figure 3a ) and VEGF-A mRNA (Figure 3b ) compared to the glucose-free condition. AICAR increased AMPK activity in cells incubated in the presence of 5 mM glucose but not in cells incubated in the absence of glucose when basal AMPK activity was high. The decrease in AMPK activity in the presence of glucose was associated with a small, but significant decrease in VEGF-A expression after 1 h, whereas the increase in AMPK activity in the The fold changes represent the maximum differences in the expression at 10 nM enterostatin on the microarray from control group (no enterostatin). Cells were incubated in the presence or absence of enterostatin for 1 h before harvesting for RNA isolation.
Enterostatin inhibits angiogenesis M Park et al presence of 5 mM glucose was associated with an increase in VEGF-A mRNA levels.
Discussion
The F1-ATPase b-subunit protein has been proposed as an enterostatin receptor. 2, [8] [9] [10] While it is present in the mitochondria as part of the ATP synthase complex, it is also present in the plasma membranes of a variety of cell and tissue types, 8, [11] [12] [13] [14] [15] including adipocytes, hepatocytes and a variety of human tumor cell lines. In the plasma membrane, the b-subunit is probably complexed with the other components of the F1-ATPase catalytic core (the a-and g-subunit proteins) that have also been localized in the plasma membrane. 12 Plasma membrane F1-ATPase appears to have a number of functions. 23 In some tumor cell lines, the b-subunit acts as a target for natural killer and lymphokine-activated killer cells. 15 The b-subunit has also been identified as an apolipoprotein A-1 receptor that functions in hepatic high density lipoprotein (HDL) endocytosis, 11 in addition to acting as an enterostatin receptor.
Finally, the a-subunit is a receptor for angiostatin and inhibits vascularization and proliferation of human umbilical vein epithelial cells through inhibition of cell surface ATP metabolism. 12, 13 Since angiostatin has been shown to bind to the a-subunit protein and inhibit angiogenesis and since the a-subunit is probably present in the membrane either as a heterodimer with the b-subunit or as the full F1-ATPase complex (a, b, g, d and e in mitochondrial membrane), we reasoned that enterostatin binding to the b-subunit might also effect angiogenesis. The data we report in this study show that enterostatin was effective in inhibiting angiogenesis in two different in vitro model systems of angiogenesis. The human adipose tissue appeared to be more sensitive to enterostatin than the human umbilical vein epithelial cell system. The reason for this is unclear but may reflect different receptor number or Enterostatin inhibits angiogenesis M Park et al signaling pathway activities between the tissues or different breakdown rates of enterostatin in the two systems. The observation of effects in two models suggests that enterostatin is affecting a general pathway of angiogenesis rather than a component that is specific to adipose tissue alone. In both cases, the inhibition showed a U-shaped dose-response curve. A similar U-shaped dose-response curve has been observed for the feeding response 24 and probably reflects the presence of two binding sites for enterostatin on the b-subunit protein, a high-affinity site to which enterostatin binds to initiate its biological effects and a lower affinity site to which both the enterostatin antagonist b-casomorphin and enterostatin will bind to inhibit this biological response. 8 Adipose tissue is a highly vascularized tissue that has the capacity to grow throughout life. A capillary network surrounds each adipocyte and the growth of new adipose mass is dependent upon the development of new vasculature. 25 This relationship has encouraged the use of angiogenic blockers as a method to prevent weight gain and induce weight loss. Indeed, a number of angiogenic blockers were shown to be effective in either inducing weight loss or was associated with reduced food intake and increased fatty acid oxidation. 27 The mechanism of this reduction in food intake is unclear and it may reflect, at least in part, direct central nervous system effects to induce a conditioned taste aversion. 28 Likewise the angiogenic or angiostatic factors responsible for regulation of adipose tissue development are unclear. Voros et al., 29 in studying expression of a large number of pro-and antiangiogenic factors in murine models of obesity, were unable to show any link with changes in expression of the various splice forms of VEGF (A, B or C) or of their receptors while the decrease in angiopoietin-2 and increase in thrombospondin-1 would produce an antiangiogenic effect rather than proangiogenic. A role for placental growth factor (PIGF) in mice is suggested by the resistance to high-fat-induced obesity and the reduction in adipose tissue blood vessel density in PIGF À/À mice. 30 In human obesity, a number of angiogenic factors are increased in the circulation, including VEGF A, C and D, angiopoietin-2 and angiogenin. 31 Further, VEGF expression in human adipose tissue is induced by both the inflammatory cytokine interleukin-6 and insulin, 32, 33 both of which are increased in obesity. The F1-ATPase in the plasma membrane has been suggested to act as either an ATP synthase or an ATP hydrolase to regulate extracellular ATP/ADP concentrations. [12] [13] [14] This activity may be reflected directly in changes in intracellular ATP/ADP concentrations through plasma membrane transport of the nucleotides or could act through purinergic P2 receptors to modulate intracellular signaling. In human primary myocyte cultures, 6 we showed that enterostatin enhances fatty acid oxidation through activation of AMPK. However, in HepG2 cells subjected to glucoprivation for 4 h, pAMPK is highly elevated and enterostatin induces a rapid reduction in pAMPK that is associated with a reduction in expression of both VEGF and Glut1 consistent with an antiangiogenic effect. The studies with AICAR, the AMPK activator, suggest a direct link between AMPK activity and VEGF expression and support the contention that enterostatin's antiangiogenic activity may be related, at least in part, to its inhibitory effect on AMPK-induced VEGF gene expression. In this study, we have shown that enterostatin inhibits VEGF expression in HepG2 cells exposed to the angiogenic stimulus of glucoprivation. Our initial genomic analysis of the responses to enterostatin in GT1-7 cells also identified numerous angiogenic-related genes in addition to VEGF that are regulated by enterostatin. We do not know if enterostatin has a similar effect on expression of these genes in adipose tissue at this time. However, we have shown that chronic administration of enterostatin is associated with weight loss and reduction in adipose mass that appears to be only partly related to the reduction in food intake. 34, 35 It is possible that an antiangiogenic effect of enterostatin may contribute to an enterostatin-induced loss of body weight by promoting adipose tissue loss and increasing the availability of fatty acids for oxidation. To date we have only shown the antiangiogenic effect of enterostatin in vitro in culture systems. Further studies are required to confirm this response in vivo and to show if enterostatin will inhibit tumor growth. However, this is the first report of an enterostatin effect on angiogenesis. It also provides further evidence for a role of the plasma membrane F1-ATPase complex in regulating tissue growth.
